TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00531856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled carbon monoxide
Description: 0.7 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled carbon monoxide
Description: 0.7 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled carbon monoxide
Description: 2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled carbon monoxide
Description: 2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled carbon monoxide
Description: 3.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled carbon monoxide
Description: 3.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Carbon Monoxide
Description: 3.5 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Carbon Monoxide
Description: 3.5 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Carbon Monoxide
Description: 2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Carbon Monoxide
Description: 2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant.
Study: NCT03460951

Intervention type: DIAGNOSTIC_TEST
Intervention: cervical MRI
Description: Cervical MRI will be performed in all of the patients and controls on a 3.0-T scanner (Discovery MR750, General Electric (GE) Medical Systems, Milwaukee, WI, USA)

Intervention type: DIAGNOSTIC_TEST
Intervention: cervical MRI
Description: Cervical MRI will be performed in all of the patients and controls on a 3.0-T scanner (Discovery MR750, General Electric (GE) Medical Systems, Milwaukee, WI, USA)

Intervention type: DIAGNOSTIC_TEST
Intervention: cervical MRI
Description: Cervical MRI will be performed in all of the patients and controls on a 3.0-T scanner (Discovery MR750, General Electric (GE) Medical Systems, Milwaukee, WI, USA)
Study: NCT02127281

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prevena
Description: Device will be applied at end of procedure over closed incision.
Study: NCT02552342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study: NCT01095692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic Organ Prolapse and Suburethral TOT implantation
Description: Procedure/Surgery: Pelvic Organ Prolapse intervention and Suburethral TOT implantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Organ Prolapse intervention
Description: Procedure/Surgery: Pelvic Organ Prolapse intervention
Study: NCT02148484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure for Adolescents

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Client Centered Therapy
Study: NCT04047147

Intervention type: OTHER
Intervention: Enrollment in the Million Hearts CVD Risk Reduction Model
Description: The intervention is at a provider organization level and all eligible beneficiaries enrolled by participants will be considered exposed. Intervention organizations receive payments to:~* Risk stratify eligible Medicare FFS beneficiaries~* Provide CVD care management to high-risk beneficiaries~* Collect and report clinical data to CMS via the Million Hearts Data Registry and participate in learning system activities~Participating organizations receive payments for each eligible beneficiary they risk stratify. In model year 1, the organizations receive a fixed payment per beneficiary per month to provide cardiovascular management. In model years 2-5, the organizations receive a risk reduction payment that is scaled based on reductions in 10-year predicted risk scores among their cohort of high-risk beneficiaries.

Intervention type: OTHER
Intervention: Enrollment in control provider organizations
Description: Control organizations receive payments to collect and report clinical data on their eligible Medicare FFS beneficiaries, but are not asked to calculate CVD risk scores or otherwise change their clinical care.
Study: NCT03850639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based exposure therapy
Description: The treatment is a three week long cognitive behavior therapy. It is based mainly on the principles of exposure; i.e. the participant is instructed to approach the memory of the traumatic event and situations they since the traumatic events are associated with fear and anxiety. Other interventions include psychoeducation, and breathing retraining to facilitate exposure.
Study: NCT03955237

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drug: dextrose containing infusion
Description: Drug: infusing dextrose containing or non glucose fluid according to blood glucose level

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drug: dextrose containing infusion
Description: Drug: infusing dextrose containing or non glucose fluid according to blood glucose level

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drug: dextrose containing infusion
Description: Drug: infusing dextrose containing or non glucose fluid according to blood glucose level
Study: NCT01123265

Intervention type: DRUG
Intervention: Methotrexate
Description: Subjects will start Methotrexate which will be escalated from 7.5 mg weekly to 15 mg/weekly over a 3 week period.
Study: NCT03775538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebral Dopamine Neurotrophic Factor
Description: Repeated intracerebral infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebral Dopamine Neurotrophic Factor
Description: Repeated intracerebral infusions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renishaw Drug Delivery System
Description: Stereotactically implanted device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renishaw Drug Delivery System
Description: Stereotactically implanted device
Study: NCT01123265

Intervention type: DRUG
Intervention: Anti-TNF
Description: Anti-TNF to be administered per standard of care within the practice.
Study: NCT00060307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01336660

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Equine F(ab')2 antivenom
Description: A single dose of 4 vials of Equine F(ab')2 antivenom will be administered intravenously over 10 minute

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intensive care support plus placebo
Description: Intensive care support as needed plus placebo
Study: NCT03815669

Intervention type: PROCEDURE
Intervention: Arthroscopic subacromial decompression
Description: Arthroscopic subacromial decompression
Study: NCT03538405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supporting cushions
Description: Cushions were placed in a way that the head and four limbs were well supported, without leaving empty space between body and cushions or mattress.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Harmonic techniques
Description: Harmonic techniques (HT) is a group of manual techniques described by Lederman (2000).The goal of this techniques in this study was to reduce the muscle tone and additionally/subsequently increase the ROM.
Study: NCT03904966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: Kinesio tape will be applied on the plantar heel (the most painful area) of the patients for the treatment of plantar fasciitis, in addition to the extracorporeal shock wave therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Kinesio tape
Description: Kinesio tape will be applied on the plantar heel (the most painful area) of the patients for the treatment of plantar fasciitis, in addition to the extracorporeal shock wave therapy

Intervention type: DEVICE
Group type: OTHER
Intervention: Extracorporeal shock wave therapy
Description: Extracorporeal shock wave therapy will be used for all patients with plantar fasciitis. (5 sessions for 5-week)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Description: Extracorporeal shock wave therapy will be used for all patients with plantar fasciitis. (5 sessions for 5-week)
Study: NCT00977847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Portals for collecting Family History data
Description: Comparison of multiple portals for integrating patient generated family history data into the electronic health record.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Portals for collecting Family History data
Description: Comparison of multiple portals for integrating patient generated family history data into the electronic health record.
Study: NCT01772667

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Rehabilitation
Description: Rehabilitation program in Schoen Klinik Berchtesgadener Land
Study: NCT03773302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Description: Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 25 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
Study: NCT01799057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants randomized to metformin will be treated at a maximum dose of 2000mg per day (i.e. 1000mg twice daily for 16-18 weeks; up-titrated from 500mg twice daily for the first 2 weeks). Participants may complete the 16-18 week treatment intervention at the lower dose of 500mg twice daily if limited by side effects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to placebo will take matching oral capsules according to the same dose schedule specified for the metformin intervention.
Study: NCT03706053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Hydrochloride
Description: Midodrine Hydrochloride, enteral, 10 or 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Hydrochloride
Description: Midodrine Hydrochloride, enteral, 10 or 20 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: investigational pharmacy formulated placebo comparator
Study: NCT01885780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser-assisted Astigmatic keratotomy
Description: Laser-assisted Astigmatic keratotomy are performed by the VICTUS™ Femtosecond Laser Platform.
Study: NCT03705416

Intervention type: PROCEDURE
Intervention: Endoscopy
Description: endoscopic suturing of stomach

Intervention type: PROCEDURE
Intervention: Surgery
Description: Vertical sleeve gastrectomy (VSG) surgical reduction of stomach, or (RYGBP) , or gastric bypass procedure
Study: NCT01670266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-9054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-9054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-9054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-9054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03904966

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Extracorporeal shock wave therapy
Description: Extracorporeal shock wave therapy will be used for all patients with plantar fasciitis. (5 sessions for 5-week)
Study: NCT01854008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation more the urban circuit
Description: included in a standard rehabilitation program + the urban circuit. A total of 32 urban walking circuits were developed jointly with the town hall of Mataró(124,000 in habitants)and were included in a triptych called A PEU, FEM SALUT! Itineraris urbans per Mataró http://www.mataro.cat/web/portal/ca/salut/salut_publica/itineraris/index

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation program but not given urbane circuits
Description: Only rehabilitation program and general recommendations on physical activity and lifestyle . No urbans circuits.
Study: NCT00985257

Intervention type: DEVICE
Group type: OTHER
Intervention: DIDGET (Investigational Blood Glucose Monitoring System)
Description: Subjects with diabetes (with parent/guardian assistance, if applicable)and health care professionals (HCPs) each performed duplicate Blood Glucose (BG) tests from the subject's capillary blood on the DIDGET. To test the full range of glucose concentrations, a venipuncture was performed on some subjects to obtain enough blood for modifying (spiking or glycolyzing) to the extreme glucose concentrations. Results were compared to a laboratory glucose method - the Yellow Springs Instrument (YSI) Analyzer.
Study: NCT01515826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel)
Description: One ribbon (approximately 1-1.5 cm) administered topically in the conjunctival sac of the study eye three times daily (TID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)
Description: One drop administered topically in the conjunctival sac of the study eye four times daily (QID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
Study: NCT03963063

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy
Description: Patients in the group will follow our mini-fluid challenge test goal-directed therapy protocol, maintaining:~* individualized optimised stroke volume by mini-fluid challenge first~* keep mean arterial pressure ≧65 mmHg~* keep systolic blood pressure ≦140 mmHg~* keep cardiac index ≧ 2.5 L/min/cm2

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non goal-directed fluid therapy
Description: Patients in the group will receive standard perioperative care at the discretion of care-giving anesthesiologist, maintaining:~* keep mean arterial pressure ≧65 mmHg~* keep systolic blood pressure ≦140 mmHg
Study: NCT04591405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Attenuated Mumps vaccine (KMB-17) in phase II and III
Description: ≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)\[≥4.3 logCCID50/ml\] in 360 children (5-11 years old) on 0 day

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in phase II
Description: Freeze-dried stabilizer and diluent without mumps virus antigen in 360 children (5-11 years old) on 0 day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Attenuated Mumps vaccine (KMB-17) in phase III
Description: ≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)\[≥4.3 logCCID50/ml\] in 5640 children (5-11 years old) on 0 day

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in phase III
Description: Freeze-dried stabilizer and diluent without mumps virus antigen in 5640 children (5-11 years old) on 0 day
Study: NCT01887145

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Description: Surgery dwas done under local anesthesia injected at the portal sites only. Tourniquet was used. Each of the two skin incisions in the endoscopic procedure was 1 cm long. With the endoscope inserted from the distal portal and a hook knife inserted from the proximal portal, the transverse carpal ligament was divided from its distal edge to its proximal edge. Incisions were closed with non-absorbables sutures and a soft dressing was applied. Sutures were removed 10 days postoperatively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery
Description: Open carpal tunnel release using conventional open technique under local anesthesia and tourniquet. The incision in the open procedure extended from about 1 cm proximal to 3 cm distal to the wrist crease. The transverse carpal ligament was divided; no additional procedures were performed. a soft dressing was applied. Dressing and sutures were removed 10 days postoperatively.
Study: NCT01486121

Intervention type: OTHER
Group type: OTHER
Intervention: Therapy strategy
Description: Sedation \& mechanical ventilation
Study: NCT01500876

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 4D-CT pre-treatment scan
Description: Undergo pre-treatment 4D-CT study for treatment planning External Beam Radiation: standard fractionation (2Gy per day) or stereotactic body radiation therapy Evaluation: Repeat 4D-CT study at 3 months and 6 months post-treatment
Study: NCT00119015

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone propionate
Study: NCT02670057

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transnasal SPG block
Study: NCT03666585

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mobile application actuated rehabilitation exercise guidance
Description: Mobile applications (also known as mobile apps) are software programs developed for mobile devices such as smartphones and tablets, to teach full function following injury and involves restoring strength, flexibility, endurance, and power.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine rehabilitation exercise guidance
Description: the teach to practice full function following injury and involves restoring strength, flexibility, endurance, and power. It is achieved through various exercises and drills
Study: NCT01607645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study: NCT02327130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isomark Canary™
Description: Isomark, LLC is a Madison, Wisconsin-based company that has developed an investigational device, the Isomark Canary™, that is intended to determine the breath delta value of breath samples collected from critically ill patients.
Study: NCT04772105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5mg of BAT5906
Description: Specification: 2.5mg of BAT5906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4.0mg of BAT5906
Description: Specification: 4.0mg of BAT5906
Study: NCT01647737

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MighTeaFlow
Description: 4-6 times daily
Study: NCT01870856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Per participant's habitual prescription

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A contact lenses
Description: Silicone hydrogel single vision contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A contact lenses
Description: Hydrogel single vision contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A contact lenses
Description: Hydrogel single vision contact lenses
Study: NCT01793194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression Stockings
Description: 20-30mmg Hg maternity pantyhose compression stockings
Study: NCT03435081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT02296684

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-3475 (neoadjuvant)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-3475 (neoadjuvant)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Standard of care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy
Description: Recommended, standard of care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy
Description: Recommended, standard of care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-guided radiation therapy
Description: Recommended, standard of care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-guided radiation therapy
Description: Recommended, standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Standard of care

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-3475 (adjuvant)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood
Description: -Baseline, time of surgery (between day 14-24 inclusive), 3 months post surgery, 6 months post surgery, 9 months post surgery, 12 months post surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood
Description: -Baseline, time of surgery (between day 14-24 inclusive), 3 months post surgery, 6 months post surgery, 9 months post surgery, 12 months post surgery